Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent prior to any study-specific procedures.~* Self-reported active symptoms of OIC at screening (\<3 SBMs/week and experiencing ≥1 reported symptom of hard/lumpy stools, straining, or sensation of incomplete evacuation/anorectal obstruction in at least 25% of BMs over the previous 4 weeks); and Documented confirmed OIC (\<3 SBMs/week on average over the 2-week OIC confirmation period.~* Receiving a stable maintenance opioid regimen consisting of a total daily dose of 30 mg to 1000 mg of oral morphine, or equianalgesic amount(s) of 1 or more other opioid therapies for a minimum of 4 weeks prior to screening for non-cancer-related pain with no anticipated change in opioid dose requirement over the proposed study period as a result of disease progression.~* Willingness to stop all laxatives and other bowel regimens including prune juice and herbal products throughout the 2-week OIC confirmation period and the 12-week treatment period, and to use only bisacodyl as rescue medication if a BM has not occurred within at least 72 hours of the last recorded BM.~Exclusion Criteria:~* Patients receiving Opioid regimen for treatment of pain related to cancer.~* History of cancer within 5 years from first study visit with the exception of basal cell cancer and squamous cell skin cancer.~* Medical conditions and treatments associated with diarrhea, intermittent loose stools, or constipation.~* Other issues to the gastrointestinal tract that could impose a risk to the patient.~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Oral treatment
- 2 (Type: EXPERIMENTAL): Oral treatment
- 3 (Type: PLACEBO_COMPARATOR): Oral treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).